Condition: Alzheimer Disease · Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 1 (Disorder) · Autosomal Dominant Alzheimer Disease Due to Mutation of Presenilin 2 (Disorder) · Sponsor: University College, London
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.
This description comes directly from the study's public registry record.
Ross Paterson · +44(0)2074483875 · r.paterson@ucl.ac.uk
Lisa French · l.french@ucl.ac.uk
Always discuss trial participation with your own doctor first.
| Washington University in St. Louis | St Louis, Missouri, United States | Recruiting |
| University College London Hospitals NHS Foundation Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06372821